Table 1.
Control values for all treatment groups
| Treatment | Dose (mg kg−1) | n | Bladder capacity (ml) | Voiding efficiency (%) | Micturition threshold (mmHg) | Bladder contraction amplitude (mmHg) | Bladder contraction duration (s) | MAP (mmHg) | HR (beats min−1) |
|---|---|---|---|---|---|---|---|---|---|
| Salinea |
— |
3 |
5.12±1.56 |
60.2±20.5 |
7.86±2.03 |
25.3±5.68 |
96.3±41.2 |
105±20.3 |
201±24.5 |
| Vehicle |
— |
5 |
4.78±0.87 |
55.9±14.4 |
12.7±1.44 |
22.7±3.67 |
23.7±2.14 |
94.4±11.1 |
163±8.17 |
| Ketoprofen |
0.3 |
4 |
5.96±1.39 |
74.6±15.1 |
9.22±3.96 |
40.4±14.4 |
88.0±18.0 |
117±7.79 |
195±17.0 |
| Indomethacin |
0.3 |
4 |
5.26±1.29 |
43.8±9.41 |
10.2±2.46 |
31.1±9.39 |
41.9±14.0 |
140±10.8 |
185±20.7 |
| FR122047 |
1 |
3 |
12.3±7.50 |
51.6±26.7 |
10.5±2.27 |
15.7±6.63 |
56.4±13.1 |
125±9.53 |
210±28.9 |
| |
3 |
5 |
10.3±2.15 |
53.5±13.7 |
11.7±3.20 |
26.5±5.70 |
60.9±15.9 |
129±12.1 |
185±20.3 |
| NS398 |
1 |
3 |
11.9±2.71 |
76.6±13.2 |
8.78±2.04 |
22.0±7.91 |
105±28.4 |
119±15.4 |
204±32.9 |
| |
3 |
5 |
12.3±2.12 |
58.6±12.2 |
8.45±1.71 |
24.7±4.12 |
88.5±32.9 |
120±8.77 |
199±9.07 |
| Nimesulide |
1 |
3 |
11.9±2.71 |
76.6±13.2 |
8.78±1.96 |
22.0±7.91 |
105±28.4 |
119±15.4 |
204±32.9 |
| 3 | 6 | 6.49±1.28 | 63.2±11.7 | 14.7±2.93 | 34.4±7.82 | 112±37.1 | 116±10.5 | 194±12.9 |
a
Experiments during which saline alone was infused into the bladder for comparison with the effects of intravesical acetic acid.
All values are mean±s.e.m.